Latest News

2026 ADA | CMS’s Self-developed Innovative INHBE-Targeting siRNA Drug CMS-D008 Presents Its Preclinical Results
2026-06-08

2026 ADA | CMS’s Self-developed Innovative INHBE-Targeting siRNA Drug CMS-D008 Presents Its Preclinical Results

China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that the preclinical results of its self-developed innovative INHBE-targeting small nucleic acid drug CMS-D008 injection (“CMS-D008”), have been presented in a poster at the American Diabetes Association (ADA) 86th Scientific Sessions (June 5-8, 2026, New Orleans, USA). As the world’s largest and most authoritative annual scientific meeting in the fields of diabetes and metabolic diseases, it convened over 12,000 leading clinicians, researchers, and healthcare professionals worldwide to explore cutting-edge advances in diagnostics, therapies, and technologies.   About CMS-D008 CMS-D008 is a self-developed novel siRNA therapy administered by subcutaneous injection. It targets and reduces the hepatic expression of the inhibin subunit beta E (INHBE) gene and lowers the level of INHBE-encoded Activin E protein, which blocks Activin E-ALK7 signaling and reduces fat accumulation effectively. It demonstrates the potential for high-quality, long-term weight loss that boosts fat-specific loss while preserving muscle mass. Currently, the […]

Learn More
CMS Charity | Love Like Starlight: CMS Continues to Care for Children’s Growth
2026-06-01

CMS Charity | Love Like Starlight: CMS Continues to Care for Children’s Growth

Growing toward the light, together in warmth. With International Children’s Day approaching, China Medical System Holdings Limited (“CMS”), through its subsidiary Shenzhen Kangzhe, continued its long-standing philanthropic initiatives. Via the Charity Association of Shenzhen Nanshan, CMS donated funds to the Star Exceptional Children Rehabilitation Center in Nanshan District, Shenzhen. The donation will be used to upgrade teaching aids, add rehabilitation equipment, and provide support for frontline teachers—helping improve learning, rehabilitation, and living conditions for exceptional children. Over the years, CMS has stood side-by-side with the Center, witnessing every small step of progress in the rehabilitation and growth of these children. This enduring commitment stems from a deep compassion for special-needs children and a profound understanding of philanthropic values: their development demands patience, sustained support, and collective care from society. In addition, CMS donated 10 computers to the Green & Shine Foundation to help improve educational facilities in schools across central and western China, supporting daily teaching […]

Learn More
CMS Wins Dual Honors at the 2026 “Golden Kunpeng”: “Best Listed Company” and “Most Investable Listed Company”
2026-05-27

CMS Wins Dual Honors at the 2026 “Golden Kunpeng”: “Best Listed Company” and “Most Investable Listed Company”

On 26 May 2026, the 2026 Global Commercial Newspaper Economic Forum and the “Golden Kunpeng” China Financial Value Ranking Awards Ceremony, co-hosted by the Global Commercial Newspaper Alliance and Hong Kong Commercial Daily, was held in Hong Kong. China Medical System Holdings Limited (“CMS” or the “Group”) stood out among a broad field of participating companies on the strength of its solid fundamentals and sustainable growth outlook, winning two awards: “Best Listed Company” and “Most Investable Listed Company”. Meanwhile, based on the Group’s overall performance in innovative R&D, growth and liquidity, the Group was officially included as a constituent of the Hong Kong Commercial Daily Technology Index.     The “Best Listed Company” award provides a comprehensive assessment across core indicators including financial performance, corporate governance, ESG practices and market influence, while the “Most Investable Listed Company” award focuses on dimensions such as the sustainability of the business model, financial soundness and industry growth potential. […]

Learn More

The news on this page is intended to share cutting-edge medical information and is for academic reference only by medical and health professionals, not for advertising purposes. CMS does not recommend any drugs, medical devices and/or indications. The news information on this page is for reference only. Please follow the advice or guidance of your doctor or other healthcare professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. If you have understood and confirmed the above content, please click OK to enter.

All News

2026 ADA | CMS’s Self-developed Innovative INHBE-Targeting siRNA Drug CMS-D008 Presents Its Preclinical Results
2026-06-08
CMS Charity | Love Like Starlight: CMS Continues to Care for Children’s Growth
2026-06-01
CMS Wins Dual Honors at the 2026 “Golden Kunpeng”: “Best Listed Company” and “Most Investable Listed Company”
2026-05-27
China Medical System’s Innovative Drug Highly Selective TYK2 Inhibitor CMS-D001 is Approved for Drug Clinical Trials for Ulcerative Colitis and Crohn’s Disease
2026-05-26
CMS 34th Anniversary | Moving with Time, Growing for Tomorrow
2026-05-13
CMS Signed An Exclusive Commercialization and Supply Agreement for Marketed Originator Intravenous Iron Products Monofer® and Cosmofer®
2026-04-27
CMS: NDA for the Seasonal Allergic Rhinitis Indication of Class 1 Innovative Drug MG-K10 Accepted in China
2026-04-23
CMS Included in S&P Global Sustainability Yearbook (China Edition) for the Fourth Consecutive Year
2026-04-14
Performance Returns to Growth Trajectory丨CMS (867.HK, 8A8.SG) 2025 Annual Performance Report in One Picture
2026-03-16
CMS: New Drug for Renal Anaemia Desidustat Tablets Approved in China
2026-03-13